Metavia Inc., a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced positive results from its ongoing collaboration with Syntekabio, Inc., an AI-driven drug discovery company. The partnership leverages Syntekabio’s proprietary DeepMatcher® platform to confirm key therapeutic targets for Metavia’s candidate Vanoglipel. The AI-modeling results demonstrated strong inflammatory and cardiometabolic target engagement, supporting the further development of Vanoglipel for conditions such as MASH and potentially type 2 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77714) on February 04, 2026, and is solely responsible for the information contained therein.